Table 1: Summary of Existing Diethylstilbestrol Cohorts
| Cohort (Reference) | Selection of Study Participants | Type of Study | Estimated Mean Dosage | Persons Exposed | Controls |
|---|---|---|---|---|---|
| g | n | ||||
| DESAD (35)* | Daughters selected through review of maternal prenatal records and referrals | Cohort | 4.2† | 4104 | 1033 |
| DES Mothers Study (36)* |
Mothers traced through review of prenatal records | Cohort | Unknown | 3029 | 3029 |
| Mayo Clinic Sons Study (70) | Sons traced through review of maternal prenatal records | Cohort | 1.4 | 828 | 676 |
| Connecticut Mothers Study (37) | Mothers selected through review of prenatal records | Cohort | 2.1 | 3315 | 1405 |
| Dieckmann and Colleagues (15) | Pregnant women enrolled in randomized clinical trials; daughters and sons identified through follow-up studies | Randomized clinical trial | 11.5 | 826 mothers 414 daughters 426 sons |
804 mothers 393 daughters 423 sons |
| BRMC Study (18)* | Pregnant diabetic women enrolled in randomized clinical trial; daughters and sons identified through follow-up study | Randomized clinical trial | 16.3 | 79 | 72 |
| British Randomized Trial (40) | Pregnant women enrolled in randomized clinical trial; daughters and sons identified through follow-up study | Randomized clinical trial | 11.5 | 379 mothers 144 daughters 177 sons |
371 mothers 170 daughters 163 sons |
| Registry for Research on Carcinogensis (41) | Women with clear-cell cervicovaginal cancer reported to registry | Referral-based registry | Unknown | 586‡ | 0 |
| * BRMC = British Medical Council; DES = diethylstilbestrol; DESAD = Diethylstilbestrol Adenosis Project † Median dosage based on 26% of cohort whose DES dosage and duration of DES use unknown ‡ Presumed to have been exposed. Of these, 60% (351) have confirmed DES exposure |
|||||